IL128994A
(en)
|
1996-09-25 |
2004-12-15 |
Zeneca Ltd |
History of quinoline and naphthyridine and their salts, processes for their preparation, pharmaceutical preparations containing them and their use as medicines
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
DE69838172T2
(de)
|
1997-08-22 |
2008-04-10 |
Astrazeneca Ab |
Oxindolylchinazolinderivate als angiogenesehemmer
|
TR200100560T2
(tr)
|
1998-08-18 |
2002-05-21 |
The Regents Of The University Of California |
EGF-R Antagonistlerinin uygulanmasıyla nefes yolunda mukus üretiminin önlenmesi
|
ES2211175T3
(es)
*
|
1998-09-29 |
2004-07-01 |
Wyeth Holdings Corporation |
Inhibidores de proteinas de tipo tirosina quinasas a base de 3-cianoquinolinas sustituidas.
|
CN1144786C
(zh)
*
|
1998-09-29 |
2004-04-07 |
美国氰胺公司 |
作为蛋白质酪氨酸激酶抑制剂的取代的3-氰基喹啉
|
US6288082B1
(en)
|
1998-09-29 |
2001-09-11 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
US6297258B1
(en)
|
1998-09-29 |
2001-10-02 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
AU2004200300A1
(en)
*
|
1998-09-29 |
2004-02-19 |
Wyeth Holdings Corporation |
Substituted 3-cyanoquinolines as Protein Tyrosine Kinases Inhibitors
|
GB9904103D0
(en)
|
1999-02-24 |
1999-04-14 |
Zeneca Ltd |
Quinoline derivatives
|
CA2361174C
(en)
*
|
1999-02-27 |
2009-10-27 |
Boehringer Ingelheim Pharma Kg |
4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
|
ATE264328T1
(de)
*
|
1999-04-21 |
2004-04-15 |
Wyeth Corp |
Substituierte 3-cyano-(1.7), (1.5) und (1.8)naphthyridininhibitoren von tyrosin kinasen
|
US6548496B2
(en)
|
1999-04-21 |
2003-04-15 |
American Cyanamid Company |
Substituted 3-cyano-[1.7], [1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases
|
US6355636B1
(en)
|
1999-04-21 |
2002-03-12 |
American Cyanamid Company |
Substituted 3-cyano-[1.7],[1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases
|
GB9910580D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
GB9910577D0
(en)
*
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
GB9910579D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
PT1731511E
(pt)
*
|
1999-06-21 |
2015-11-13 |
Boehringer Ingelheim Pharma |
Heterociclos bicíclicos, medicamentos contendo estes compostos, a sua utilização e processos para a sua preparação
|
US7192698B1
(en)
|
1999-08-17 |
2007-03-20 |
Purdue Research Foundation |
EphA2 as a diagnostic target for metastatic cancer
|
US6927203B1
(en)
|
1999-08-17 |
2005-08-09 |
Purdue Research Foundation |
Treatment of metastatic disease
|
MXPA02004366A
(es)
|
1999-11-05 |
2002-11-07 |
Astrazeneca Ab |
Derivados de quinazolina como inhibidores vegf.
|
ATE353320T1
(de)
*
|
1999-12-29 |
2007-02-15 |
Wyeth Corp |
Tricyclische proteinkinasehemmer
|
US6638929B2
(en)
|
1999-12-29 |
2003-10-28 |
Wyeth |
Tricyclic protein kinase inhibitors
|
BR0109165A
(pt)
*
|
2000-03-13 |
2003-04-22 |
American Cyanamid Co |
Método de tratamento de pólipos colÈnicos
|
US6384051B1
(en)
|
2000-03-13 |
2002-05-07 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps
|
US6521618B2
(en)
|
2000-03-28 |
2003-02-18 |
Wyeth |
3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
|
AR035851A1
(es)
*
|
2000-03-28 |
2004-07-21 |
Wyeth Corp |
3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
|
US6608048B2
(en)
|
2000-03-28 |
2003-08-19 |
Wyeth Holdings |
Tricyclic protein kinase inhibitors
|
US6627634B2
(en)
|
2000-04-08 |
2003-09-30 |
Boehringer Ingelheim Pharma Kg |
Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
|
MXPA02009855A
(es)
*
|
2000-04-08 |
2003-03-27 |
Boehringer Ingelheim Pharma |
Heterociclos biciclicos, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparacion.
|
WO2002002534A1
(en)
*
|
2000-07-03 |
2002-01-10 |
Astrazeneca Ab |
Quinazolines with therapeutic use
|
US6576644B2
(en)
*
|
2000-09-06 |
2003-06-10 |
Bristol-Myers Squibb Co. |
Quinoline inhibitors of cGMP phosphodiesterase
|
US7101976B1
(en)
|
2000-09-12 |
2006-09-05 |
Purdue Research Foundation |
EphA2 monoclonal antibodies and methods of making and using same
|
US7253184B2
(en)
|
2000-11-02 |
2007-08-07 |
Astrazeneca Ab |
4-Substituted quinolines as antitumor agents
|
AU2002210714A1
(en)
|
2000-11-02 |
2002-06-11 |
Astrazeneca Ab |
Substituted quinolines as antitumor agents
|
US7019012B2
(en)
|
2000-12-20 |
2006-03-28 |
Boehringer Ingelheim International Pharma Gmbh & Co. Kg |
Quinazoline derivatives and pharmaceutical compositions containing them
|
CA2431679A1
(en)
*
|
2000-12-29 |
2002-07-11 |
Wyeth |
Method for the regioselective preparation of substituted benzo[g]quinoline-3-carbonitriles and benzo[g]quinazolines
|
SE0101675D0
(sv)
*
|
2001-05-11 |
2001-05-11 |
Astrazeneca Ab |
Novel composition
|
US6713462B2
(en)
*
|
2001-06-21 |
2004-03-30 |
Ariad Pharmaceuticals, Inc. |
Quinolinones and uses thereof
|
EP1412367A4
(en)
|
2001-06-21 |
2006-05-03 |
Ariad Pharma Inc |
NEW CHINOLINE AND ITS USE
|
US7501516B2
(en)
|
2001-07-16 |
2009-03-10 |
Astrazeneca Ab |
Quinoline derivatives and their use as tyrosine kinase inhibitors
|
UA77200C2
(en)
|
2001-08-07 |
2006-11-15 |
Wyeth Corp |
Antineoplastic combination of cci-779 and bkb-569
|
UA77469C2
(en)
|
2001-11-27 |
2006-12-15 |
White Holdings Corp |
3-cyanoquinolines as egf-r and her2 kinase inhibitors
|
AU2002347359A1
(en)
*
|
2001-12-05 |
2003-06-17 |
Astrazeneca Ab |
Quinoline derivatives
|
GB0129099D0
(en)
*
|
2001-12-05 |
2002-01-23 |
Astrazeneca Ab |
Chemical compounds
|
WO2003047582A1
(en)
*
|
2001-12-05 |
2003-06-12 |
Astrazeneca Ab |
Quinoline derivatives as antitumour agents
|
AU2002347336A1
(en)
*
|
2001-12-05 |
2003-06-17 |
Astrazeneca Ab |
Quinoline derivatives
|
DE60328461D1
(de)
*
|
2002-01-28 |
2009-09-03 |
Ube Industries |
Verfahren zur herstellung eines chinazolin-4-onderivats
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US7235537B2
(en)
|
2002-03-13 |
2007-06-26 |
Array Biopharma, Inc. |
N3 alkylated benzimidazole derivatives as MEK inhibitors
|
ES2549159T3
(es)
|
2002-03-13 |
2015-10-23 |
Array Biopharma, Inc. |
Derivados de bencimidazol N3-alquilados como inhibidores de MEK
|
US7009053B2
(en)
*
|
2002-04-30 |
2006-03-07 |
Yungjin Pharmaceuticals Co., Ltd. |
Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
DE10221018A1
(de)
|
2002-05-11 |
2003-11-27 |
Boehringer Ingelheim Pharma |
Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
|
EP1521747B1
(en)
|
2002-07-15 |
2018-09-05 |
Symphony Evolution, Inc. |
Receptor-type kinase modulators and methods of use
|
HUP0600340A3
(en)
|
2002-07-15 |
2011-06-28 |
Genentech Inc |
Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
|
DK2345671T3
(en)
|
2002-09-27 |
2016-02-15 |
Xencor Inc |
Optimized Fc variants and methods for their formation
|
GB0225579D0
(en)
|
2002-11-02 |
2002-12-11 |
Astrazeneca Ab |
Chemical compounds
|
US20060167026A1
(en)
*
|
2003-01-06 |
2006-07-27 |
Hiroyuki Nawa |
Antipsychotic molecular-targeting epithelial growth factor receptor
|
CL2004000016A1
(es)
*
|
2003-01-21 |
2005-04-15 |
Wyeth Corp |
Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
|
WO2004069249A1
(en)
*
|
2003-02-03 |
2004-08-19 |
Astrazeneca Ab |
3-cyano-quinoline derivatives as non-receptor tyrosine kinase inhibitors
|
WO2004069250A1
(en)
*
|
2003-02-03 |
2004-08-19 |
Astrazeneca Ab |
3-cyano-quinoline derivatives as non-receptor tyrosine kinase inhibitors
|
WO2004069827A1
(en)
*
|
2003-02-03 |
2004-08-19 |
Astrazeneca Ab |
Quinoline derivatives and use thereof as antitumor agents
|
US7223749B2
(en)
|
2003-02-20 |
2007-05-29 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
US7135575B2
(en)
|
2003-03-03 |
2006-11-14 |
Array Biopharma, Inc. |
P38 inhibitors and methods of use thereof
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US7381410B2
(en)
|
2003-03-12 |
2008-06-03 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
AU2004220525B2
(en)
|
2003-03-12 |
2011-03-31 |
Vasgene Therapeutics, Inc. |
Nucleic acid compounds for inhibiting angiogenesis and tumor growth
|
UA80607C2
(en)
|
2003-04-09 |
2007-10-10 |
White Holdings Corp |
Process for the preparation of 3-cyano-6-alkoxy-7-nitro-4-quinolines
|
WO2004108704A1
(en)
*
|
2003-06-05 |
2004-12-16 |
Astrazeneca Ab |
Pyrimidin-4-yl 3-cyanoquinoline derivatives for use in the treatment of tumours
|
WO2004108703A1
(en)
*
|
2003-06-05 |
2004-12-16 |
Astrazeneca Ab |
Pyrazinyl 3-cyanoquinoline derivatives for use in the treatment of tumours
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
KR20060065662A
(ko)
|
2003-07-31 |
2006-06-14 |
사노피-아벤티스 |
아미노퀴놀린 유도체 및 아데노신 a3 리간드로서의 이의용도
|
MXPA06001590A
(es)
*
|
2003-08-19 |
2006-05-19 |
Wyeth Corp |
Proceso para la preparacion de 4-amino-3-quinolincarbonitrilos.
|
US7144907B2
(en)
|
2003-09-03 |
2006-12-05 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
US7538120B2
(en)
|
2003-09-03 |
2009-05-26 |
Array Biopharma Inc. |
Method of treating inflammatory diseases
|
US7399865B2
(en)
*
|
2003-09-15 |
2008-07-15 |
Wyeth |
Protein tyrosine kinase enzyme inhibitors
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
CA2537812C
(en)
|
2003-09-26 |
2013-01-22 |
Exelixis, Inc. |
C-met modulators and method of use
|
US7456189B2
(en)
|
2003-09-30 |
2008-11-25 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
|
DE10349113A1
(de)
|
2003-10-17 |
2005-05-12 |
Boehringer Ingelheim Pharma |
Verfahren zur Herstellung von Aminocrotonylverbindungen
|
BR122018071808B8
(pt)
|
2003-11-06 |
2020-06-30 |
Seattle Genetics Inc |
conjugado
|
WO2005047259A1
(en)
*
|
2003-11-06 |
2005-05-26 |
Wyeth |
4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
|
US7732616B2
(en)
|
2003-11-19 |
2010-06-08 |
Array Biopharma Inc. |
Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
|
US7517994B2
(en)
|
2003-11-19 |
2009-04-14 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
DK1689233T3
(da)
|
2003-11-19 |
2012-10-15 |
Array Biopharma Inc |
Bicykliske inhibitorer af MEK
|
KR101223914B1
(ko)
|
2003-11-21 |
2013-01-18 |
어레이 바이오파마 인크. |
Akt 단백질 키나제 억제제
|
CA2549728C
(en)
|
2003-12-18 |
2015-07-21 |
Janssen Pharmaceutica N.V. |
3-cyano-quinoline derivatives with antiproliferative activity
|
UA83881C2
(en)
|
2003-12-18 |
2008-08-26 |
Янссен Фармацевтика Н.В. |
Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
|
CN1930128A
(zh)
*
|
2004-01-16 |
2007-03-14 |
惠氏公司 |
受体酪氨酸激酶抑制剂的喹啉中间体及其合成
|
SE0400284D0
(sv)
*
|
2004-02-10 |
2004-02-10 |
Astrazeneca Ab |
Novel compounds
|
TW200529846A
(en)
|
2004-02-20 |
2005-09-16 |
Wyeth Corp |
3-quinolinecarbonitrile protein kinase inhibitors
|
CN102718867A
(zh)
|
2004-03-12 |
2012-10-10 |
瓦斯基因治疗公司 |
结合ephb4、抑制血管发生和肿瘤生长的抗体
|
WO2005090406A2
(en)
|
2004-03-12 |
2005-09-29 |
Vasgene Therapeutics, Inc. |
Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
|
ES2741574T3
(es)
|
2004-03-31 |
2020-02-11 |
Massachusetts Gen Hospital |
Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico
|
ME01267B
(me)
|
2004-05-06 |
2013-06-20 |
Warner Lambert Co |
4-fenilaminokinazolin-6-ilamidi
|
KR101200133B1
(ko)
|
2004-06-01 |
2012-11-13 |
제넨테크, 인크. |
항체 약물 접합체 및 방법
|
EP1919950A1
(en)
|
2004-07-15 |
2008-05-14 |
Xencor, Inc. |
Optimized fc variants
|
CA2580141C
(en)
|
2004-09-23 |
2013-12-10 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
EP2301963A1
(en)
|
2004-09-23 |
2011-03-30 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
DK1802579T3
(da)
|
2004-10-20 |
2014-01-20 |
Merck Serono Sa |
Derivater af 3-arylaminopyridin
|
KR101027427B1
(ko)
|
2004-11-12 |
2011-04-11 |
젠코어 인코포레이티드 |
FcRn에 대하여 증가된 결합력을 갖는 Fc 변이체
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
NI200700147A
(es)
|
2004-12-08 |
2019-05-10 |
Janssen Pharmaceutica Nv |
Derivados de quinazolina inhibidores de cinasas dirigidos a multip
|
US8258145B2
(en)
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
CA2592900A1
(en)
|
2005-01-03 |
2006-07-13 |
Myriad Genetics Inc. |
Nitrogen containing bicyclic compounds and therapeutical use thereof
|
ZA200706017B
(en)
|
2005-01-21 |
2008-12-31 |
Genentech Inc |
Fixed dosing of her antibodies
|
CN102886045A
(zh)
|
2005-02-03 |
2013-01-23 |
综合医院公司 |
治疗吉非替尼耐药性癌症的方法
|
EP1850874B1
(en)
|
2005-02-23 |
2013-10-16 |
Genentech, Inc. |
Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
|
JP2008540656A
(ja)
*
|
2005-05-18 |
2008-11-20 |
ワイス |
Tpl2キナーゼの3−シアノキノリン阻害物質ならびにそれを製造および使用する方法
|
ES2333182T3
(es)
|
2005-05-18 |
2010-02-17 |
Array Biopharma, Inc. |
Derivados de 4-(fenilamino)-6-oxo-1,6-dihidropiridazina-3-carboxamida como inhibidores de mek para el tratamiento de enfermedades hiperproliferativas.
|
EP1883631A1
(en)
*
|
2005-05-25 |
2008-02-06 |
Wyeth |
Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof
|
WO2007041635A2
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
JP5324785B2
(ja)
|
2005-10-28 |
2013-10-23 |
武田薬品工業株式会社 |
複素環アミド化合物及びその用途
|
AR057854A1
(es)
|
2005-11-04 |
2007-12-19 |
Wyeth Corp |
Combinaciones antineoplasicas con inhibidor de mtor, herceptina y/o hki-272 (e)-n-{4-[3-cloro-4-(2-piridinilmetoxi) anilino]-3-ciano-7-etoxi-6-quinolinil}-4-(dimetilamino)-2-butenamida
|
CA2629244C
(en)
|
2005-11-11 |
2014-08-05 |
Boehringer Ingelheim International Gmbh |
Quinazoline derivatives for the treatment of cancer diseases
|
MY151835A
(en)
|
2006-01-31 |
2014-07-14 |
Array Biopharma Inc |
Kinase inhibitors and methods of use thereof
|
CN101516891B
(zh)
|
2006-07-06 |
2013-06-05 |
阵列生物制药公司 |
作为akt蛋白激酶抑制剂的二氢噻吩并嘧啶
|
RU2481336C2
(ru)
|
2006-07-06 |
2013-05-10 |
Эррэй Биофарма Инк. |
Циклопента(d)пиримидины в качестве ингибиторов протеинкиназ акт
|
CN101511842B
(zh)
|
2006-07-06 |
2012-10-31 |
阵列生物制药公司 |
作为akt蛋白激酶抑制剂的二氢呋喃并嘧啶
|
US8063050B2
(en)
|
2006-07-06 |
2011-11-22 |
Array Biopharma Inc. |
Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
MX2009000456A
(es)
|
2006-07-13 |
2009-01-27 |
Janssen Pharmaceutica Nv |
Derivados de quinazolina mtki.
|
PT2059536E
(pt)
|
2006-08-14 |
2014-04-14 |
Xencor Inc |
Anticorpos otimizados que visam cd19
|
EP2386655B1
(en)
|
2006-09-12 |
2014-11-19 |
Genentech, Inc. |
Methods and compositions for the diagnosis and treatment of lung cancer using KIT or KDG gene as genetic marker
|
WO2008034776A1
(en)
|
2006-09-18 |
2008-03-27 |
Boehringer Ingelheim International Gmbh |
Method for treating cancer harboring egfr mutations
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
JP5377332B2
(ja)
|
2007-02-06 |
2013-12-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法
|
MX2009008981A
(es)
|
2007-03-02 |
2009-09-02 |
Genentech Inc |
Prediccion de respuesta a un inhibidor her.
|
EP2708557A1
(en)
|
2007-05-30 |
2014-03-19 |
Xencor, Inc. |
Method and compositions for inhibiting CD32B expressing cells
|
ES2417148T3
(es)
|
2007-06-08 |
2013-08-06 |
Genentech, Inc. |
Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
|
RU2486181C2
(ru)
|
2007-07-05 |
2013-06-27 |
Эррэй Биофарма Инк. |
Пиримидилциклопентаны как ингибиторы акт-протеинкиназ
|
BRPI0813993A2
(pt)
|
2007-07-05 |
2015-06-16 |
Array Biopharma Inc |
Ciclopentanos de pirimidila como inibidores de proteína quinase akt
|
US9409886B2
(en)
|
2007-07-05 |
2016-08-09 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
US8846683B2
(en)
|
2007-07-05 |
2014-09-30 |
Array Biopharma, Inc. |
Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
|
EP2185562B1
(en)
|
2007-07-27 |
2015-12-02 |
Janssen Pharmaceutica, N.V. |
Pyrrolopyrimidines useful for the treatment of proliferative diseases
|
AU2008287427B2
(en)
|
2007-08-13 |
2014-10-09 |
Vasgene Therapeutics, Inc. |
Cancer treatment using humanized antibodies that bind to EphB4
|
CN101148439B
(zh)
*
|
2007-09-14 |
2011-06-22 |
东南大学 |
一种吉非替尼的制备方法
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
SI2235059T1
(sl)
|
2007-12-26 |
2015-06-30 |
Xencor, Inc. |
Fc variante s spremenjeno vezjo na fcrn
|
NZ586346A
(en)
|
2008-01-09 |
2012-02-24 |
Array Biopharma Inc |
Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
|
NZ586720A
(en)
|
2008-01-09 |
2012-11-30 |
Array Biopharma Inc |
Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
PL2245026T3
(pl)
|
2008-02-07 |
2013-01-31 |
Boehringer Ingelheim Int |
Spirocykliczne heterocykle, leki zawierające te związki, ich zastosowanie i sposób ich produkcji
|
DE102008009609A1
(de)
|
2008-02-18 |
2009-08-20 |
Freie Universität Berlin |
Substituierte 4-(Indol-3-yl)chinazoline und deren Verwendung und Herstellung
|
NZ589143A
(en)
|
2008-05-14 |
2012-02-24 |
Genomic Health Inc |
Colorectal cancer response prediction based on AREG EREG DUSP6 and SLC26A3 expression levels
|
EP2915532B1
(en)
|
2008-06-17 |
2016-10-19 |
Wyeth LLC |
Antineoplastic combinations containing hki-272 and vinorelbine
|
JP5681108B2
(ja)
|
2008-08-04 |
2015-03-04 |
ワイス・エルエルシー |
4−アニリノ−3−シアノキノリンとカペシタビンの抗新生物薬の組合せ
|
PT2307376E
(pt)
|
2008-08-04 |
2016-02-26 |
Merck Patent Gmbh |
Novos compostos de fenilamino-isonicotinamida
|
CA2733153C
(en)
|
2008-08-08 |
2016-11-08 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
|
US8993630B2
(en)
|
2008-11-10 |
2015-03-31 |
Bayer Intellectual Property Gmbh |
Substituted sulphonamido phenoxybenzamides
|
CA2743449C
(en)
|
2008-11-12 |
2016-10-18 |
Ariad Pharmaceuticals, Inc. |
Pyrazinopyrazines and derivatives as kinase inhibitors
|
CA2995880C
(en)
|
2009-01-16 |
2021-01-05 |
Exelixis, Inc. |
Processes for preparing n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
|
RU2011139363A
(ru)
|
2009-04-06 |
2013-05-20 |
ВАЙЕТ ЭлЭлСи |
Схема лечения рака молочной железы с использованием нератиниба
|
ES2731901T3
(es)
|
2009-07-06 |
2019-11-19 |
Boehringer Ingelheim Int |
Proceso para el secado de BIBW2992, de sus sales y de formulaciones farmacéuticas sólidas que comprenden este ingrediente activo
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
CN102020639A
(zh)
*
|
2009-09-14 |
2011-04-20 |
上海恒瑞医药有限公司 |
6-氨基喹唑啉或3-氰基喹啉类衍生物、其制备方法及其在医药上的应用
|
WO2011047788A1
(en)
|
2009-10-21 |
2011-04-28 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted benzosulphonamides
|
WO2011047795A1
(en)
|
2009-10-21 |
2011-04-28 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted benzosulphonamides
|
CN102574782B
(zh)
|
2009-10-21 |
2014-10-08 |
拜耳知识产权有限责任公司 |
取代的卤代苯氧基苯甲酰胺衍生物
|
JP6184695B2
(ja)
|
2009-12-04 |
2017-08-23 |
ジェネンテック, インコーポレイテッド |
多重特異性抗体、抗体アナログ、組成物、及び方法
|
MX2012008049A
(es)
|
2010-01-12 |
2012-08-01 |
Hoffmann La Roche |
Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,.
|
WO2011107664A1
(en)
|
2010-03-04 |
2011-09-09 |
Hospital District Of Southwest Finland |
Method for selecting patients for treatment with an egfr inhibitor
|
WO2011113802A2
(en)
|
2010-03-17 |
2011-09-22 |
F. Hoffmann-La Roche Ag |
Imidazopyridine compounds, compositions and methods of use
|
EP2552957A4
(en)
|
2010-03-29 |
2013-11-20 |
Zymeworks Inc |
ANTIBODIES HAVING ENHANCED OR DELETED EFFECTIVE FUNCTION
|
RU2012148699A
(ru)
|
2010-04-16 |
2014-05-27 |
Дженентек, Инк. |
Foxo3a как прогностический биомаркер для эффективности ингибитора пути киназы pi3k/акт
|
US20130053375A1
(en)
*
|
2010-05-07 |
2013-02-28 |
Glaxo Group Limited |
Amino-quinolines as kinase inhibitors
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
US9187458B2
(en)
*
|
2010-06-09 |
2015-11-17 |
Tianjin Hemay Bio-Tech Co., Ltd. |
Cyanoquinoline derivatives
|
SG187064A1
(en)
*
|
2010-07-14 |
2013-02-28 |
Zhejiang Beta Pharma Inc |
NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
|
UY33549A
(es)
*
|
2010-08-10 |
2012-01-31 |
Glaxo Group Ltd |
Quinolil aminas como agentes inhibidores de las quinasas
|
WO2012035039A1
(en)
|
2010-09-15 |
2012-03-22 |
F. Hoffmann-La Roche Ag |
Azabenzothiazole compounds, compositions and methods of use
|
CA2816188A1
(en)
|
2010-10-29 |
2012-05-03 |
Marion Hitchcock |
Substituted phenoxypyridines
|
WO2012065161A2
(en)
|
2010-11-12 |
2012-05-18 |
Scott & White Healthcare |
Antibodies to tumor endothelial marker 8
|
CN103313987A
(zh)
|
2010-11-19 |
2013-09-18 |
弗·哈夫曼-拉罗切有限公司 |
吡唑并吡啶化合物、吡唑并吡啶化合物以及它们作为tyk2抑制剂的用途
|
WO2012085176A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
|
BR112013022307A2
(pt)
|
2011-03-04 |
2020-09-24 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
aminoquinolinas como inibidores de quinase
|
WO2012122513A2
(en)
|
2011-03-10 |
2012-09-13 |
Omeros Corporation |
Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
|
CN102675287A
(zh)
*
|
2011-03-11 |
2012-09-19 |
江苏恒瑞医药股份有限公司 |
(e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用
|
KR20140022053A
(ko)
|
2011-04-01 |
2014-02-21 |
제넨테크, 인크. |
Akt 및 mek 억제제 화합물의 조합물, 및 사용 방법
|
CN103857395A
(zh)
|
2011-04-01 |
2014-06-11 |
基因泰克公司 |
Akt抑制剂化合物和阿比特龙的组合及使用方法
|
WO2012160130A1
(en)
|
2011-05-25 |
2012-11-29 |
Universite Paris Descartes |
Erk inhibitors for use in treating spinal muscular atrophy
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
WO2013007765A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Fused tricyclic compounds for use as inhibitors of janus kinases
|
MX2014001595A
(es)
|
2011-08-12 |
2014-04-14 |
Hoffmann La Roche |
Compuestos de imidazol, composiciones y metodos de uso.
|
EP3392274A1
(en)
|
2011-08-12 |
2018-10-24 |
Omeros Corporation |
Anti-fzd10 monoclonal antibodies and methods for their use
|
TWI547494B
(zh)
|
2011-08-18 |
2016-09-01 |
葛蘭素史克智慧財產發展有限公司 |
作為激酶抑制劑之胺基喹唑啉類
|
WO2013041539A1
(en)
|
2011-09-20 |
2013-03-28 |
F. Hoffmann-La Roche Ag |
Imidazopyridine compounds, compositions and methods of use
|
BR112014010644A2
(pt)
|
2011-11-04 |
2017-04-25 |
Hoffmann La Roche |
novos derivados de aril-quinolina
|
CN103204822B
(zh)
|
2012-01-17 |
2014-12-03 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途
|
CN104379602B
(zh)
|
2012-03-08 |
2017-05-03 |
哈洛齐梅公司 |
具有条件活性的抗表皮生长因子受体抗体及其使用方法
|
US20130259867A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
CN103539783A
(zh)
*
|
2012-07-12 |
2014-01-29 |
江苏恒瑞医药股份有限公司 |
一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法
|
AR092530A1
(es)
|
2012-09-13 |
2015-04-22 |
Glaxosmithkline Llc |
Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
|
TWI592417B
(zh)
|
2012-09-13 |
2017-07-21 |
葛蘭素史克智慧財產發展有限公司 |
胺基喹唑啉激酶抑制劑之前藥
|
RU2662810C2
(ru)
|
2013-02-21 |
2018-07-31 |
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Хиназолины в качестве ингибиторов киназы
|
BR112015022545A2
(pt)
|
2013-03-13 |
2017-07-18 |
Constellation Pharmaceuticals Inc |
compostos de pirazolo e os usos disso
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
CN103275001B
(zh)
*
|
2013-06-14 |
2015-02-18 |
苏州明锐医药科技有限公司 |
4-氨基-3-喹啉甲腈衍生物的制备方法
|
MX2016002794A
(es)
|
2013-09-05 |
2016-09-13 |
Genentech Inc |
Compuestos antiproliferativos.
|
EP3043822A1
(en)
|
2013-09-11 |
2016-07-20 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Compositions for preparing cardiomyocytes
|
EP3044236A2
(en)
|
2013-09-12 |
2016-07-20 |
Halozyme, Inc. |
Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
|
AR097894A1
(es)
|
2013-10-03 |
2016-04-20 |
Hoffmann La Roche |
Inhibidores terapéuticos de cdk8 o uso de los mismos
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Kras g12c之抑制劑
|
EP3083687A2
(en)
|
2013-12-17 |
2016-10-26 |
F. Hoffmann-La Roche AG |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
HUE047699T2
(hu)
|
2013-12-17 |
2020-05-28 |
Hoffmann La Roche |
Eljárások rákbetegségek kezelésére PD-1-tengelyhez kötõdõ antagonisták és taxánok alkalmazásával
|
US9242965B2
(en)
|
2013-12-31 |
2016-01-26 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
|
EP3094736A4
(en)
|
2014-01-14 |
2017-10-25 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
|
WO2015153514A1
(en)
|
2014-03-31 |
2015-10-08 |
Genentech, Inc. |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
|
CR20160500A
(es)
|
2014-03-31 |
2016-12-14 |
Genentech Inc |
Anticuerpos anti-ox40 y métodos de uso
|
CN107074823B
(zh)
|
2014-09-05 |
2021-05-04 |
基因泰克公司 |
治疗性化合物及其用途
|
EP3193866A1
(en)
|
2014-09-19 |
2017-07-26 |
Genentech, Inc. |
Use of cbp/ep300 and bet inhibitors for treatment of cancer
|
EP3204516B1
(en)
|
2014-10-06 |
2023-04-26 |
Dana-Farber Cancer Institute, Inc. |
Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
|
JP6783230B2
(ja)
|
2014-10-10 |
2020-11-11 |
ジェネンテック, インコーポレイテッド |
ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物
|
WO2016073380A1
(en)
|
2014-11-03 |
2016-05-12 |
Genentech, Inc. |
Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
BR112017009151A2
(pt)
|
2014-11-03 |
2018-03-06 |
Genentech, Inc. |
ensaios para detectar subgrupos imunológicos de célula t e métodos de uso dos mesmos
|
WO2016073282A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
MA40940A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
MA40943A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
WO2016077375A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Bromodomain inhibitors and uses thereof
|
US20160166685A1
(en)
|
2014-11-17 |
2016-06-16 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
EP3632915A1
(en)
|
2014-11-27 |
2020-04-08 |
Genentech, Inc. |
4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
|
JP2018508183A
(ja)
|
2014-12-23 |
2018-03-29 |
ジェネンテック, インコーポレイテッド |
化学療法耐性癌を治療及び診断する組成物及び方法
|
WO2016109546A2
(en)
|
2014-12-30 |
2016-07-07 |
Genentech, Inc. |
Methods and compositions for prognosis and treatment of cancers
|
EP3242874B1
(en)
|
2015-01-09 |
2018-10-31 |
Genentech, Inc. |
Pyridazinone derivatives and their use in the treatment of cancer
|
CN107406418B
(zh)
|
2015-01-09 |
2021-10-29 |
基因泰克公司 |
4,5-二氢咪唑衍生物及其作为组蛋白脱甲基酶(kdm2b)抑制剂的用途
|
EP3242872B1
(en)
|
2015-01-09 |
2019-07-03 |
Genentech, Inc. |
(piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer
|
EP3250571B1
(en)
|
2015-01-29 |
2022-11-30 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
JP6636031B2
(ja)
|
2015-01-30 |
2020-01-29 |
ジェネンテック, インコーポレイテッド |
治療用化合物およびその使用
|
MA41598A
(fr)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
MA41866A
(fr)
|
2015-03-31 |
2018-02-06 |
Massachusetts Gen Hospital |
Molécules à auto-assemblage pour l'administration ciblée de médicaments
|
CN107709364A
(zh)
|
2015-04-07 |
2018-02-16 |
豪夫迈·罗氏有限公司 |
具有激动剂活性的抗原结合复合体及使用方法
|
EP3280708B1
(en)
|
2015-04-10 |
2021-09-01 |
Araxes Pharma LLC |
Substituted quinazoline compounds and methods of use thereof
|
HRP20201900T4
(hr)
|
2015-05-12 |
2024-06-07 |
F. Hoffmann - La Roche Ag |
Terapeutski i dijagnostički postupci kod raka
|
IL294138A
(en)
|
2015-05-29 |
2022-08-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
AU2016274585A1
(en)
|
2015-06-08 |
2017-12-14 |
Genentech, Inc. |
Methods of treating cancer using anti-OX40 antibodies
|
EP3303397A1
(en)
|
2015-06-08 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
KR20180018538A
(ko)
|
2015-06-17 |
2018-02-21 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
|
NZ738525A
(en)
*
|
2015-07-06 |
2019-03-29 |
Gilead Sciences Inc |
Cot modulators and methods of use thereof
|
WO2017007694A1
(en)
|
2015-07-06 |
2017-01-12 |
Gilead Sciences, Inc. |
6-amino-quinoline-3-carbonitrils as cot modulators
|
JP6946270B2
(ja)
|
2015-08-26 |
2021-10-06 |
ファンダシオン デル セクトル プーブリコ エスタタル セントロ ナショナル デ インベスティゲーショネス オンコロジカス カルロス 3(エフ エス ピー クニオ) |
タンパク質キナーゼ阻害剤としての縮合三環化合物
|
JP2018532990A
(ja)
|
2015-09-04 |
2018-11-08 |
オービーアイ ファーマ,インコーポレイテッド |
グリカンアレイおよび使用の方法
|
JP6764474B2
(ja)
|
2015-09-25 |
2020-09-30 |
ジェネンテック, インコーポレイテッド |
抗tigit抗体及び使用方法
|
WO2017058805A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
EP3356359B1
(en)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
US10858343B2
(en)
|
2015-09-28 |
2020-12-08 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10875842B2
(en)
|
2015-09-28 |
2020-12-29 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
CN108473435A
(zh)
|
2015-10-05 |
2018-08-31 |
纽约市哥伦比亚大学理事会 |
自噬潮和磷脂酶d的活化剂以及包括tau的蛋白聚集体的清除和蛋白质病的治疗
|
CA3005089A1
(en)
|
2015-11-16 |
2017-05-26 |
Araxes Pharma Llc |
2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
|
DK3389662T3
(da)
|
2015-12-16 |
2022-02-28 |
Genentech Inc |
Fremgangsmåde til fremstilling af tricykliske PI3K-inhibitorforbindelser og fremgangsmåder til anvendelse af disse til behandling af cancer
|
CA3006529A1
(en)
|
2016-01-08 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
KR20180119632A
(ko)
|
2016-02-29 |
2018-11-02 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
CN109311995A
(zh)
|
2016-03-29 |
2019-02-05 |
台湾浩鼎生技股份有限公司 |
抗体、药物组合物和方法
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
AU2017248766A1
(en)
|
2016-04-15 |
2018-11-01 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
AU2017250296A1
(en)
|
2016-04-15 |
2018-11-01 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
AU2017249229A1
(en)
|
2016-04-15 |
2018-10-04 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
BR112018071683A2
(pt)
|
2016-04-22 |
2019-02-19 |
Obi Pharma, Inc. |
método para tratar um câncer de mama, método para tratamento de um tumor em um paciente, método para tratar um indivíduo sofrendo com câncer por imunoterapia, método para induzir/melhorar uma resposta imune em um indivíduo, método para melhorar a vacina obi-822 induzida pela resposta imune em um indivíduo necessitando da mesma, método para identificar um paciente adequado para terapia do câncer e método para determinar o prognóstico do tratamento do câncer ou resposta do fármaco de um paciente
|
WO2017194554A1
(en)
|
2016-05-10 |
2017-11-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combinations therapies for the treatment of cancer
|
MA45146A
(fr)
|
2016-05-24 |
2021-03-24 |
Constellation Pharmaceuticals Inc |
Dérivés de pyrazolopyridine pour le traitement du cancer
|
JP7160688B2
(ja)
|
2016-05-24 |
2022-10-25 |
ジェネンテック, インコーポレイテッド |
Cbp/ep300の複素環式インヒビターおよびがんの処置におけるそれらの使用
|
ES2963807T3
(es)
|
2016-06-08 |
2024-04-02 |
Xencor Inc |
Tratamiento de enfermedades relacionadas con la IgG4 con anticuerpos anti-CD19 de reticulación a CD32B
|
CN109312407A
(zh)
|
2016-06-08 |
2019-02-05 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
US10059695B2
(en)
|
2016-06-30 |
2018-08-28 |
Gilead Sciences, Inc. |
Cot modulators and methods of use thereof
|
AU2017302038B2
(en)
|
2016-07-27 |
2024-03-21 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycan compositions and uses thereof
|
WO2018023121A1
(en)
|
2016-07-29 |
2018-02-01 |
Obi Pharma, Inc. |
Human antibodies, pharmaceutical compositions and methods
|
CN109963871A
(zh)
|
2016-08-05 |
2019-07-02 |
豪夫迈·罗氏有限公司 |
具有激动活性的多价及多表位抗体以及使用方法
|
EP3497129A1
(en)
|
2016-08-08 |
2019-06-19 |
H. Hoffnabb-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
WO2018064510A1
(en)
|
2016-09-29 |
2018-04-05 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
AU2017339517B2
(en)
|
2016-10-06 |
2024-03-14 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
CN110267678A
(zh)
|
2016-10-29 |
2019-09-20 |
霍夫曼-拉罗奇有限公司 |
抗mic抗体和使用方法
|
CA3044274A1
(en)
|
2016-11-21 |
2018-05-24 |
Obi Pharma, Inc. |
Conjugated biological molecules, pharmaceutical compositions and methods
|
US11358959B2
(en)
|
2017-01-26 |
2022-06-14 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
US11279689B2
(en)
|
2017-01-26 |
2022-03-22 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
|
US11274093B2
(en)
|
2017-01-26 |
2022-03-15 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
EP3573970A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
EP3573967A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused hetero-hetero bicyclic compounds and methods of use thereof
|
ES2953595T3
(es)
|
2017-03-01 |
2023-11-14 |
Hoffmann La Roche |
Procedimientos diagnósticos y terapéuticos para el cáncer
|
KR20190136076A
(ko)
|
2017-04-13 |
2019-12-09 |
에프. 호프만-라 로슈 아게 |
암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
|
BR112019024674A2
(pt)
|
2017-05-25 |
2020-06-16 |
Araxes Pharma Llc |
Inibidores covalentes da kras
|
JP2020521741A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
がんの処置のための化合物およびその使用の方法
|
US11639346B2
(en)
|
2017-05-25 |
2023-05-02 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
|
KR20240006698A
(ko)
|
2017-07-21 |
2024-01-15 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
MX2020000903A
(es)
|
2017-08-11 |
2020-07-22 |
Genentech Inc |
Anticuerpos anti-cd8 y usos de los mismos.
|
AU2018329925A1
(en)
|
2017-09-08 |
2020-03-05 |
F. Hoffmann-La Roche Ag |
Diagnostic and therapeutic methods for cancer
|
WO2019084395A1
(en)
|
2017-10-27 |
2019-05-02 |
University Of Virginia Patent Foundation |
COMPOUNDS AND METHODS FOR REGULATING, LIMITING OR INHIBITING AVIL EXPRESSION
|
KR20200075860A
(ko)
|
2017-11-06 |
2020-06-26 |
제넨테크, 인크. |
암의 진단 및 치료 방법
|
JP7480048B2
(ja)
|
2018-01-26 |
2024-05-09 |
エグゼリクシス, インコーポレイテッド |
キナーゼ依存的障害を処置するための化合物
|
CN111757735B
(zh)
|
2018-01-26 |
2023-09-22 |
埃克塞里艾克西斯公司 |
用于治疗激酶依赖性病症的化合物
|
US11708367B2
(en)
|
2018-01-26 |
2023-07-25 |
Exelixis, Inc. |
Compounds for the treatment of kinase-dependent disorders
|
CN111836831A
(zh)
|
2018-02-26 |
2020-10-27 |
豪夫迈·罗氏有限公司 |
用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药
|
EP3797173A2
(en)
|
2018-05-21 |
2021-03-31 |
Nanostring Technologies, Inc. |
Molecular gene signatures and methods of using same
|
US20200030443A1
(en)
|
2018-06-23 |
2020-01-30 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
US11203645B2
(en)
|
2018-06-27 |
2021-12-21 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
CN108752248A
(zh)
*
|
2018-07-17 |
2018-11-06 |
常州大学 |
一种合成1-(3-乙氧基-4-甲氧基)苯基-2-甲磺酰基乙胺的方法
|
WO2020018789A1
(en)
|
2018-07-18 |
2020-01-23 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
CN112805267B
(zh)
|
2018-09-03 |
2024-03-08 |
豪夫迈·罗氏有限公司 |
用作tead调节剂的甲酰胺和磺酰胺衍生物
|
KR20210063330A
(ko)
|
2018-09-19 |
2021-06-01 |
제넨테크, 인크. |
방광암에 대한 치료 및 진단 방법
|
JP7475336B2
(ja)
|
2018-09-21 |
2024-04-26 |
ジェネンテック, インコーポレイテッド |
トリプルネガティブ乳癌のための診断方法
|
EP3867646A1
(en)
|
2018-10-18 |
2021-08-25 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
EP3921443A1
(en)
|
2019-02-08 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
JP2022522185A
(ja)
|
2019-02-27 |
2022-04-14 |
エピアクシス セラピューティクス プロプライエタリー リミテッド |
T細胞機能を評価して治療法に対する応答を予測するための方法および薬剤
|
EP3931220A1
(en)
|
2019-02-27 |
2022-01-05 |
F. Hoffmann-La Roche AG |
Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
CN114269376A
(zh)
|
2019-05-03 |
2022-04-01 |
豪夫迈·罗氏有限公司 |
用抗pd-l1抗体治疗癌症的方法
|
TWI770527B
(zh)
|
2019-06-14 |
2022-07-11 |
美商基利科學股份有限公司 |
Cot 調節劑及其使用方法
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
AR119887A1
(es)
|
2019-09-04 |
2022-01-19 |
Genentech Inc |
Agentes de unión a cd8 y sus usos
|
AU2020351782A1
(en)
|
2019-09-26 |
2022-04-21 |
Exelixis, Inc. |
Pyridone compounds and methods of use in the modulation of a protein kinase
|
PE20221110A1
(es)
|
2019-09-27 |
2022-07-11 |
Genentech Inc |
Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
|
WO2021083949A1
(en)
|
2019-10-29 |
2021-05-06 |
F. Hoffmann-La Roche Ag |
Bifunctional compounds for the treatment of cancer
|
CN115066613A
(zh)
|
2019-11-06 |
2022-09-16 |
基因泰克公司 |
用于治疗血液癌症的诊断和治疗方法
|
MX2022005775A
(es)
|
2019-11-13 |
2022-06-09 |
Genentech Inc |
Compuestos terapeuticos y metodos de uso.
|
KR20220113790A
(ko)
|
2019-12-13 |
2022-08-16 |
제넨테크, 인크. |
항-ly6g6d 항체 및 사용 방법
|
CA3164995A1
(en)
|
2019-12-20 |
2021-06-24 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
IL294800A
(en)
|
2020-01-27 |
2022-09-01 |
Genentech Inc |
Methods of treating cancer with an antibody to an anti-ti antagonist
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
AU2021249010A1
(en)
|
2020-03-30 |
2022-10-06 |
Gilead Sciences, Inc. |
Solid forms of (S)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
|
AU2021245924B2
(en)
|
2020-04-02 |
2024-02-29 |
Gilead Sciences, Inc. |
Process for preparing a Cot inhibitor compound
|
EP4127724A1
(en)
|
2020-04-03 |
2023-02-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
CN115885050A
(zh)
|
2020-04-28 |
2023-03-31 |
基因泰克公司 |
用于非小细胞肺癌免疫疗法的方法和组合物
|
CA3181820A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
BR112022025801A2
(pt)
|
2020-06-18 |
2023-10-03 |
Hoffmann La Roche |
Métodos para tratar um paciente e para tratar um paciente com escc avançado, kit, anticorpo, uso de um anticorpo e uso de um antagonista de ligação
|
EP4172621A1
(en)
|
2020-06-30 |
2023-05-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
|
US20230266322A1
(en)
|
2020-06-30 |
2023-08-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
|
US20230265098A1
(en)
*
|
2020-07-02 |
2023-08-24 |
Enliven Therapeutics, Inc. |
Alkyne quinazoline derivatives as inhibitors of erbb2
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
WO2022031749A1
(en)
|
2020-08-03 |
2022-02-10 |
Genentech, Inc. |
Diagnostic and therapeutic methods for lymphoma
|
TW202214615A
(zh)
|
2020-08-10 |
2022-04-16 |
大陸商上海和譽生物醫藥科技有限公司 |
一種egfr抑制劑及其製備方法和應用
|
EP4196612A1
(en)
|
2020-08-12 |
2023-06-21 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
CA3193273A1
(en)
|
2020-08-27 |
2022-03-03 |
Enosi Therapeutics Corporation |
Methods and compositions to treat autoimmune diseases and cancer
|
AU2021347232A1
(en)
|
2020-09-23 |
2023-04-27 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
IL301547A
(en)
|
2020-10-05 |
2023-05-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
|
US20230107642A1
(en)
|
2020-12-18 |
2023-04-06 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
CR20230382A
(es)
|
2021-02-12 |
2023-09-06 |
Hoffmann La Roche |
Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer
|
WO2022178205A1
(en)
|
2021-02-19 |
2022-08-25 |
Exelixis, Inc. |
Pyridone compounds and methods of use
|
AU2022280025A1
(en)
|
2021-05-25 |
2023-12-07 |
Erasca, Inc. |
Sulfur-containing heteroaromatic tricyclic kras inhibitors
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
CA3226019A1
(en)
|
2021-07-20 |
2023-01-26 |
Ags Therapeutics Sas |
Extracellular vesicles from microalgae, their preparation, and uses
|
TW202321261A
(zh)
|
2021-08-10 |
2023-06-01 |
美商伊瑞斯卡公司 |
選擇性kras抑制劑
|
TW202340212A
(zh)
|
2021-11-24 |
2023-10-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
TW202332429A
(zh)
|
2021-11-24 |
2023-08-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
WO2023144127A1
(en)
|
2022-01-31 |
2023-08-03 |
Ags Therapeutics Sas |
Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
|
TW202342018A
(zh)
|
2022-03-04 |
2023-11-01 |
美商奇奈特生物製藥公司 |
Mek激酶抑制劑
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
CN115057776B
(zh)
*
|
2022-06-15 |
2023-08-22 |
必维申瓯质量技术服务温州有限公司 |
2-萘甲酸乙酯衍生物的合成方法
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033389A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024085242A2
(en)
|
2022-10-21 |
2024-04-25 |
Kawasaki Institute Of Industrial Promotion |
Non-fouling or super stealth vesicle
|
WO2024088808A1
(en)
|
2022-10-24 |
2024-05-02 |
Ags Therapeutics Sas |
Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|